Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118481
Author
Yoshifuji, Ayumi The Japanese Society for Dialysis Therapy|Tokyo Saiseikai Central Hospital
Toda, Masataro Tokyo Saiseikai Central Hospital
Ryuzaki, Munekazu The Japanese Society for Dialysis Therapy|Tokyo Saiseikai Central Hospital
Kikuchi, Kan The Japanese Society for Dialysis Therapy
Kawai, Toru The Japanese Society for Dialysis Therapy
Sakai, Ken The Japanese Society for Dialysis Therapy
Oyama, Emi The Japanese Society for Dialysis Therapy
Koinuma, Masayoshi Teikyo Heisei University
Katayama, Kazuhiko Kitasato University
Uehara, Yuki The Japanese Society for Dialysis Therapy
Ohmagari, Norio The Japanese Society for Dialysis Therapy
Kanno, Yoshihiko The Japanese Society for Dialysis Therapy
Kon, Hirofumi The Japanese Society for Dialysis Therapy
Shinoda, Toshio The Japanese Society for Dialysis Therapy
Takano, Yaoko The Japanese Society for Dialysis Therapy
Tanaka, Junko The Japanese Society for Dialysis Therapy
Hora, Kazuhiko The Japanese Society for Dialysis Therapy
Nakazawa, Yasushi The Japanese Society for Dialysis Therapy
Hasegawa, Naoki The Japanese Society for Dialysis Therapy
Hanafusa, Norio The Japanese Society for Dialysis Therapy
Hinoshita, Fumihiko The Japanese Society for Dialysis Therapy
Morikane, Keita The Japanese Society for Dialysis Therapy
Nakamoto, Hidetomo The Japanese Society for Dialysis Therapy
Takemoto, Yoshiaki The Japanese Society for Dialysis Therapy
Keywords
COVID-19
Hemodialysis
Vaccination
Adverse reactions
Content Type
Journal Article
Description
Background: Dialysis patients are predisposed to severe disease and have a high mortality rate in coronavirus disease 2019 (COVID-19) due to their comorbidities and immunocompromised conditions. Therefore, dialysis patients should be prioritized for vaccination. This study aimed to examine how long the effects of the vaccine are maintained and what factors affect antibody titers.
Methods: Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (Control group), receiving two doses of BNT162b2 vaccine, were recruited through the Japanese Society for Dialysis Therapy (JSDT) Web site in July 2021. Anti-SARS-CoV-2 immunoglobulin (IgG) (SARS-CoV-2 IgG titers) was measured before vaccination, 3 weeks after the first vaccination, 2 weeks after the second vaccination, and 3 months after the second vaccination, and was compared between Control group and HD group. Factors affecting SARS-CoV-2 IgG titers were also examined using multivariable regression analysis and stepwise regression analysis (least AIC). In addition, we compared adverse reactions in Control and HD groups and examined the relationship between adverse reactions and SARS-CoV-2 IgG titers.
Results: Our study enrolled 123 participants in the Control group (62.6% men, median age 67.0 years) and 206 patients in the HD group (64.1% men, median age 66.4 years). HD group had significantly lower SARS-CoV-2 IgG titers at 3 weeks after the first vaccination (p < 0.0001), 2 weeks after second vaccination (p = 0.0002), and 3 months after the second vaccination (p = 0.045) than Control group. However, the reduction rate of SARS-CoV-2 IgG titers between 2 weeks and 3 months after the second vaccination was significantly smaller in HD group than in Control (p = 0.048). Stepwise regression analysis revealed that dialysis time was identified as the significant independent factors for SARS-CoV-2 IgG titers at 2 weeks after the second vaccination in HD group (p = 0.002) and longer dialysis time resulted in higher maximum antibody titers. The incidences of fever and nausea after the second vaccination were significantly higher in the HD group (p = 0.039 and p = 0.020). Antibody titers in those with fever were significantly higher than those without fever in both groups (HD: p = 0.0383, Control: p = 0.0096).
Conclusion: HD patients had significantly lower antibody titers than age- and sex-matched non-dialysis individuals over 3 months after vaccination. Dialysis time was identified as a factor affecting SARS-CoV-2 IgG titers in HD group, with longer dialysis time resulting in higher maximum SARS-CoV-2 IgG titers.
Journal Title
Renal Replacement Therapy
ISSN
20591381
Publisher
BioMed Central|Springer Nature
Volume
8
Start Page
39
Published Date
2022-08-19
Rights
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
rrt_8_39.pdf 1.13 MB
language
eng
TextVersion
Publisher
departments
Medical Sciences